<em>Ex Vivo</em> Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Adriana D. Corben; Mohammad M. Uddin; Brooke Crawford; Mohammad Farooq; Shanu Modi; John Gerecitano; Gabriela Chiosis; Mary L. Alpaugh

doi:10.3791/52157

/

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

<em>Ex Vivo</em> Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

JoVE Journal
Medicine

A subscription to JoVE is required to view this content. Sign in or start your free trial.

JoVE Journal Medicine

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

14,635 Views

•

08:29 min

•

October 02, 2014

DOI:

10.3791/52157-v

DOI:

10.3791/52157-v

•

08:29 min

October 02, 2014

•

9 Views

Adriana D. Corben*¹, Mohammad M. Uddin*², Brooke Crawford³, Mohammad Farooq⁴, Shanu Modi⁵, John Gerecitano⁵, Gabriela Chiosis², Mary L. Alpaugh⁶

¹Department of Pathology,Memorial Sloan Kettering Cancer Center, ²Molecular Pharmacology and Chemistry Program,Memorial Sloan Kettering Cancer Center, ³Department of Radiology,Weill Cornell Medical College, ⁴Department of Medicine,Memorial Sloan Kettering Cancer Center, ⁵Department of Oncology,Memorial Sloan Kettering Cancer Center, ⁶Department of Surgery,Memorial Sloan Kettering Cancer Center

Summary

Established cancer cell lines and xenografts have been the mainstay of cancer research for the past several decades. However, recent evidence suggests that therapeutic response is greatly influenced by the tumor cell microenvironment. Therefore, we have developed an ex vivo analysis of primary tumor specimens for drug development purposes.